In order to meet the criterion of genetic engineering drugs, overcoming antigenicity against human and removing the His-tag from rLm-PHB2 would provide the opportunity for the application of rLm-PHB2 as a potential anti-tumor drug in the future clinical studies. This evidence concerns the gene PHB2 and neoplasm.